Kiora Pharmaceuticals (KPRX) Change in Accured Expenses (2014 - 2026)

Kiora Pharmaceuticals (KPRX) has 13 years of Change in Accured Expenses data on file, last reported at -$389063.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 64.12% year-over-year to -$389063.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 million (down 170.77% YoY) and the FY2025 annual result came in at -$2.3 million, down 171.25% from the prior year.
• Change in Accured Expenses declined to -$389063.0 in Q1 2026, from $233904.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.0 million in Q4 2024 to a low of -$1.1 million in Q1 2025.
• A 5-year average of $41413.2 and a median of $72375.0 in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses jumped 3081.99% — and 2025, when it sank 1078.47%.
• Tracing KPRX's Change in Accured Expenses over 5 years: stood at $92038.0 in 2022, then slumped by 207.91% to -$99315.0 in 2023, then jumped by 3081.99% to $3.0 million in 2024, then sank by 92.1% to $233904.0 in 2025, then slumped by 266.33% to -$389063.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$389063.0 (Q1 2026), $233904.0 (Q4 2025), and -$412015.0 (Q3 2025), per Business Quant data.